arrow
J

Joseph D. Mancias

Dana-Farber Cancer Institute
H指数:48
被引数:2.0万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Targeting macrophage ferritin heavy chain mitigates ferroptosis and lung injury in experimental acute respiratory distress syndrome

靶向巨噬细胞铁蛋白重链可减轻铁死亡和实验性急性呼吸窘迫综合征中的肺损伤

2026-06-270
OAAI
Pancreatic Reirradiation: A Multi-Institutional Retrospective Analysis of Feasibility, Tolerability, and Clinical Outcomes

胰腺再放疗:一项多机构回顾性分析可行性、耐受性及临床结局

2026-01-010
PRE
Stereotactic magnetic resonance imaging-guided adaptive radiotherapy: a pooled analysis of a master prospective trial

立体定向磁共振成像引导自适应放射治疗:一项主前瞻性试验的合并分析

2025-09-010
PRE
Integrative genomic identification of therapeutic targets for pancreatic cancer

整合基因组学鉴定胰腺癌的治疗靶点

2025-08-210
PREAI
De novo pyrimidine biosynthesis inhibition synergizes with BCL-XL targeting in pancreatic cancer

从头嘧啶生物合成抑制与BCL-XL靶向在胰腺癌中协同作用

2025-07-300
OA
An in vivo barcoded CRISPR-Cas9 screen identifies Ncoa4-mediated ferritinophagy as a dependence in Tet2-deficient hematopoiesis

体内条形码CRISPR-Cas9筛选鉴定出Ncoa4介导的铁蛋白自噬是Tet2缺陷型造血的依赖因素

Blood
IF23.1
2025-06-160
OA
An open label, phase II trial of ERK inhibition alone and in combination with autophagy inhibition in patients with metastatic cancreatic cancer
2024-09-150
PRE
Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer

胰腺癌对致癌KRAS抑制的耐药机制

2024-07-057
PRE
Stereotactic MR-guided on-table adaptive radiation therapy (SMART) for borderline resectable and locally advanced pancreatic cancer: A multi-center, open-label phase 2 study
2024-02-0131
OAAI
A Multi-Institutional Phase 2 Trial of Ablative 5-Fraction Stereotactic Magnetic Resonance-Guided On-Table Adaptive Radiation Therapy for Borderline Resectable and Locally Advanced Pancreatic Cancer
2023-11-0150
OAAI
Gender-Affirming Surgery and Cancer : Considerations for Radiation Oncologists for Pelvic Radiation in Transfeminine Patients

性别肯定手术和癌症: 跨女性患者盆腔放射的放射肿瘤学家考虑

2023-10-018
OAAI